cis-Dihydrothebainon | 847-86-9

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: cis-Dihydrothebainon
• 英文别名: (1R,10S)-3-hydroxy-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
• CAS: 847-86-9；2934-63-6；15172-51-7；88196-19-4
• 化学式: C₁₈H₂₃NO₃
• 分子量: 301.386
• InChiKey: CDGFTOARGCEWKI-VZGYSGOJSA-N

物化性质

• 熔点：
  176 °C
• 沸点：
  470.3±45.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• (+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof
  申请人：Mallinckrodt LLC

  公开号：US11142502B2

  公开（公告）日：2021-10-12

  The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.

  本发明提供了包含Toll样受体9（TLR9）拮抗剂活性的(+)-吗啡烷，以及使用(+)-吗啡烷治疗疼痛的方法。本发明还提供了包含(+)-吗啡南和阿片激动剂/单胺再摄取抑制剂的药物组合物，以及使用该组合物治疗疼痛的方法。
• (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
  申请人：Trawick Bobby N.

  公开号：US20110015219A1

  公开（公告）日：2011-01-20

  The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as a method for identifying (+)-morphinans that may be therapeutically effective by determining whether the (+)-morphinan inhibits the activation of TLR9. Also provided are methods of using the (+)-morphinans comprising TLR9 antagonist activity to treat conditions such as traumatic pain, neuropathic pain, inflammatory disorders, acetaminophen toxicity, autoimmune disorders, neurodegenerative disorders, and cancer.
• (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF
  申请人：Mallinckrodt LLC

  公开号：US20200172488A1

  公开（公告）日：2020-06-04

  The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.